Labcorp Debuts First FDA-Cleared Blood Test for Alzheimer's, Stock Up

Key Takeaways Labcorp Holdings, Inc. (LH) has announced the nationwide availability of the Lumipulse pTau-217/Beta Amyloid 42 Ratio — the first FDA-cleared blood-based in-vitro diagnostic (IVD) test to assist in diagnosing Alzheimer's disease. Developed by Fujirebio Diagnostics, Inc., the test helps through early detection of the amyloid plaques associated with the disease in appropriate patients. The latest test builds on and replaces a similar pTau-217/Beta Amyloid 42 Ratio test that Labcorp introduced in ...